Medical Use
Viltepso is an antisense oligonucleotide designed for the treatment of Duchenne muscular dystrophy (DMD) in patients with a specific mutation in the DMD gene that allows for exon 53 skipping.
Recommended Dosage: Administer Viltepso at a dose of 80 mg/kg once a week through a 60-minute intravenous infusion.
In case a dose is missed, it should be given as soon as possible after the scheduled time.
Warning & Precautions
Before initiating treatment with Viltolarsen, measure serum cystatin C, perform a urine dipstick test, and determine the urine protein-to-creatinine ratio.
For patients with known renal impairment, closely monitor their condition while on Viltolarsen.
During Viltepso therapy, conduct monthly urine dipstick tests and measure serum cystatin C and urine protein-to-creatinine ratio every three months.
If there is a persistent increase in serum cystatin C or proteinuria, consult a pediatric nephrologist.
Consider measuring the glomerular filtration rate before starting treatment.
Note that due to reduced skeletal muscle mass, serum creatinine may not be a reliable indicator of kidney function.
Documentation Availability
Documents required to import VILTEPSO to India?
VILTEPSO (Viltolarsen) capsules can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing VILTEPSO (Cancer Treatment Medicines) from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the generic name for the trade name drug Viltepso®?
The generic name for Viltepso® is Viltolarsen.
Who manufactures Viltepso®?
Viltepso® is manufactured by NS Pharma, Inc.
Is Viltepso® FDA approved?
Yes, Viltepso® received FDA approval on August 12, 2020.
What is Viltepso®?
Viltepso (active ingredient: Viltolarsen) is a Morpholino antisense oligonucleotide used to treat Duchenne muscular dystrophy (DMD).
What dosage forms are available for Viltepso®?
Viltepso® is available as an injection: 250 mg/5 mL (50 mg/mL) solution in a single-dose vial for intravenous use.
How does Viltepso® work?
Viltepso works by “hiding” exon 53, allowing cells to skip this exon and enabling the remaining exons to align correctly, producing a shortened version of the dystrophin protein.
What are the common side effects of Viltepso®?
Common side effects include injection site reactions, upper respiratory tract infections, cough, and fever.
How should Viltepso® be stored?
Store Viltepso® at 2°C to 8°C (36°F to 46°F). Do not freeze.
What is the cost of Viltepso® in India?
The cost of Viltepso® 250 mg in India is competitive with other antisense oligonucleotide medications for DMD. For procurement, you can order through https://rx4u.in/
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
